<DOC>
	<DOCNO>NCT02996890</DOCNO>
	<brief_summary>Double blind , randomize , placebo-controlled , dose finding , multi-center , phase 1 trial 48 healthy volunteer subject . After completion screening procedure , subject randomize one four treatment group ( different dosage strength placebo ) All subject receive study treatment day 0 return day 28 . Subjects randomize treatment group two vaccination receive second treatment day 28 . Subjects return day 56 final visit .</brief_summary>
	<brief_title>Zika-Vaccine Dose Finding Study Regarding Safety , Immunogenicity Tolerability</brief_title>
	<detailed_description />
	<mesh_term>Zika Virus Infection</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy volunteer age 18 55 subject child bear potential must perform reliable method contraception immune deficiency , history HIV , HBV , HCV drug addiction vaccination within 4 week prior study plan vaccination study prior receipt Zika vaccine recent infection 1 week prior screen relevant medical history interfere aim study neoplastic disease , hematological malignancy history autoimmune disease psychological condition affect ability participate study history severe adverse reaction vaccine administration history anaphylaxis allergic reaction , abnormal lab value , concomitant medication per decision investigator use immunosuppressive drug within 30 day screen plan use study receipt blood product within 120 day screen plan use study pregnancy , unreliable contraception method decision investigator regular blood plasma donor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>